Sean K. Kelley

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 535 citations · Full text

Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety

Sean K. Kelley, Louise A. Harris, David Xie et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 442 citations

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1

Michael D. Prados, Kathleen R. Lamborn, Susan M. Chang et al. · Neuro-Oncology · 2006 · 216 citations · Full text

Pathology, Pharmacotherapy, High-grade Gliomas +17

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 132 citations · Full text

Pancreatic Cancer, Medicine, Pharmacology +6

Plasma Thyroid Hormone Kinetics Are Altered in Iron-Deficient Rats

John L. Beard, D. Brigham, Sean K. Kelley et al. · Journal of Nutrition · 1998 · 105 citations · Full text

Endocrine Mechanism, Iodine Deficiency Disorders, Physiology +11